Enovis Corporation (ENOV) Fair Value 2026

ENOV · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 6 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-28, Enovis Corporation (ENOV) trades at $24.90, versus a $55.38 median fair value across its 6 active models — 122.4% above the current price. QOC: 6.1/10. Value Trap Risk: 34/100 (LOW). 6/13 models active.

Key Facts

Ticker
ENOV
Price
$24.90
Quality Score
6.1/10
Value Trap Risk
34/100
Models Active
6/13
Last Updated
Strength: Regime Cross-Sectional suggests +244.0% upside with 49% confidence
Risk: Limited model coverage (6/13) may reduce confidence

Is Enovis Corporation (ENOV) Undervalued or Overvalued in 2026?

According to CirclFi’s 6-model valuation engine, Enovis Corporation (ENOV) appears undervalued as of : the median of 6 independent fair value estimates is $55.38, 122.4% above the current price of $24.90. Estimates range from $31.72 to $85.65. ENOV scores 6.1/10 on fundamental quality and 34/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ENOV’s +122.4% gap is wider than that market norm, and the Medical Devices sector median is -43.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Enovis Corporation Stock in 2026? →

What Fair Value Does Each Model Give ENOV?

6 Intrinsic Value Models vs. Current Price ($24.90)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Medium Conviction
 $55.48 +122.8%
Scenario · High Conviction
 $55.27 +122.0%
Relative · Medium Conviction
 $85.65 +244.0%
Unlock the Full Matrix

Access 3 additional models including PWERM, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is ENOV's Fair Value Range?

Spread across 6 independent models · $31.72 to $85.65

CirclFi's 6 active models place Enovis Corporation (ENOV) between $31.72 and $85.65 per share, a spread of 97% of the median. The median of that range — $55.38 — is the fair value CirclFi publishes for ENOV, against a current price of $24.90.

Low · Sentiment SOTPHigh · Regime Cross
$31.72median $55.38$85.65
Where the range comes from
Most bearish modelSentiment SOTP$31.72
Most bullish modelRegime Cross-Sectional$85.65
Model agreement6 bullish · 0 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on ENOV, not a CirclFi price target. How each model works →

What Is Enovis Corporation (ENOV) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Enovis Corporation. Trading at $24.90 against an estimated intrinsic value of $55.38, 6 of 6 active models flag meaningful upside of +122.4% at the median. The most optimistic model, Regime Cross, places fair value at $85.65 (+244.0%), while Sentiment SOTP — the most conservative — estimates $31.72 (+27.4%). This +216.6% gap reflects genuine analytical uncertainty about Enovis Corporation's intrinsic worth.

What Do the Models Say About ENOV?

6 of 13 models are currently active for ENOV. All 6 active models suggest the stock trades below fair value. Taken together, their median fair value for ENOV is $55.38 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ENOV Rank in Medical Devices?

Among 159 Medical Devices stocks, ENOV ranks #88 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

Enovis Corporation's positioning within the Medical Devices segment means that patent cliff exposure plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.

Is ENOV a Value Trap?

CirclFi's Value Trap algorithm assigns ENOV a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for Enovis Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Enovis Corporation earns a quality score of 6.1/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +216.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ENOV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ENOV's 6 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Enovis Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

BBNXBeta Bionics, Inc.QOC 6.1RPIDRapid Micro Biosystems, Inc.QOC 6.1CBLLCeriBell, Inc.QOC 6.1NMTCNeuroOne Medical Technologies CorporationQOC 6.1AVRAnteris Technologies Global Corp.QOC 6.1AIDX20/20 Biolabs, Inc.QOC 6.0HSCSHeartSciences Inc.QOC 4.9SYKStryker CorporationQOC 9.0IRTCiRhythm Holdings, Inc.QOC 7.1IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: BBNX · RPID · CBLL · NMTC · AVR · AIDX · HSCS · SYK · IRTC · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to ENOV?

7 companies across all industries closest to ENOV’s Quality of Company score of 6.1/10.

TOONKartoon Studios Inc.QOC 6.1PWPower REITQOC 6.1INMBINmune Bio Inc.QOC 6.1JDZGJIADE LimitedQOC 6.1TSHATaysha Gene Therapies, Inc.QOC 6.1XRAYDENTSPLY SIRONA Inc.QOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TOON · PW · INMB · JDZG · TSHA · XRAY · NVDA

Where Does ENOV Sit in CirclFi's Medical Devices Rankings?

ENOV is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Enovis Corporation’s Valuation?

What is Enovis Corporation's intrinsic value in 2026?

CirclFi puts Enovis Corporation (ENOV)'s intrinsic value at $55.38 — the median of 6 independent model estimates as of 2026-08-28, ranging from $31.72 to $85.65. The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ENOV overvalued or undervalued right now?

At $24.90, 6 of 6 active models suggest ENOV may be undervalued, while 0 indicate potential overvaluation. The median of all 6 fair value estimates is $55.38, 122.4% above the current price of $24.90 — a consensus view that ENOV is undervalued. The assessment depends on which methodology best fits Enovis Corporation's business model in Medical Devices.

What does a Quality of Company score of 6.1 mean for ENOV?

Enovis Corporation's QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ENOV?

CirclFi analyzes ENOV with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ENOV?

Of the 6 models currently active on ENOV, Regime Cross-Sectional is the most bullish at $85.65 per share, and Sentiment SOTP is the most bearish at $31.72. CirclFi's published fair value for ENOV is the median of that range, $55.38, not either extreme. The gap between the two ends equals 97% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is ENOV a value trap in 2026?

Enovis Corporation's Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 6-model valuation engine, Enovis Corporation (ENOV) has a median fair value of $55.38 — 122.4% above the current price of $24.90 — as of 2026-08-28.” Source: circlfi.com/stock/ENOV/ · Methodology
Primary sources for this ENOV valuation
  • Financial statements: Enovis Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001420800) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ENOV as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on ENOV.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for ENOV Unlock All 6 — $39/mo